Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Core Insights - Equillium, Inc. is hosting a virtual key opinion leader event on November 5, 2025, focusing on the unmet needs and treatment landscape in ulcerative colitis, particularly the potential of Aryl Hydrocarbon Receptor (AhR) modulation [1][2] Company Overview - Equillium is a clinical-stage biotechnology company specializing in developing novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical needs [5] - The company's pipeline includes several novel immunomodulatory assets targeting immuno-inflammatory pathways [5] Event Details - The event will feature experts Francisco J. Quintana, PhD, and Brian Feagan, MD, discussing the evolving treatment landscape in ulcerative colitis and the promise of AhR targeting [2] - Company management will present a scientific overview of EQ504, an oral, colon-targeted AhR modulator, and its preclinical data demonstrating its mechanism of action [3] - A live Q&A session will follow the presentations, and a replay will be available on Equillium's website [4]